215713-39-6

Breceptin Chemical Structure
215713-39-6

Chemical Structure

Breceptin

Synonym(s): B 9870

  • CAS No.: 215713-39-6
  • Formula:C136H200N38O28
  • Molecular Weight:2815.28

IUPAC Name: (2S,2'S)-2,2'-(((2S,2'S,3aS,3a'S,7aS,7a'S)-1,1'-((6S,6'S,9S,9'S,12R,12'R)-1,1'-((2S,2'S,4R,4'R)-((2S,2'S)-1,1'-((2S,5R,16R,19S)-2,5,16,19-tetrakis(3-guanidinopropyl)-4,7,14,17-tetraoxo-3,6,15,18-tetraazaicosanedioyl)bis(pyrrolidine-1,2-diyl-2-carbonyl))bis(4-hydroxypyrrolidine-1,2-diyl))bis(6,12-bis(2,3-dihydro-1H-inden-2-yl)-9-(hydroxymethyl)-1,4,7,10-tetraoxo-2,5,8,11-tetraazatridecan-13-oyl))bis(octahydro-1H-indole-1,2-diyl-2-carbonyl))bis(azanediyl))bis(5-guanidinopentanoic acid)

InChIKey: DRGMTQZFSANFRJ-LLIQBGFESA-N

SMILES: O=C(NCC(N[C@H](C(N[C@H](C(N[C@@H](C(N1[C@@]2([C@]([H])(C[C@H]1C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)CCCC2)[H])=O)C3CC4=C(C3)C=CC=C4)=O)CO)=O)C5CC6=C(C5)C=CC=C6)=O)[C@H]7N(C([C@H]8N(C([C@@H](NC([C@H](NC(CCCCCCC(N[C@@H](C(N[C@H](C(N9[C@H](C(N%10[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@@H](C(N%11[C@@]%12([C@]([H])(C[C@H]%11C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)CCCC%12)[H])=O)C%13CC%14=C(C%13)C=CC=C%14)=O)CO)=O)C%15CC%16=C(C%15)C=CC=C%16)=O)=O)C[C@H](C%10)O)=O)CCC9)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCC8)=O)C[C@@H](C7)O

Biological Activity: Breceptin (B 9870) is an antagonist of the bradykinin B1/B2 receptor (B1/B2R). Breceptin exhibits an irreversible antagonist effect on B2R, inhibiting the vasodilation induced by Bradykinin (HY-P0206) in the rabbit carotid vein contraction experiment. B-9870 shows partial agonist properties in HEK 293 cells with high expression of B2R, and can activate ERK1/2 phosphorylation, calcium ion mobilization, arachidonic acid release, and receptor internalization. Breceptin can be used in research to inhibit breast cancer and non-small cell lung cancer[1].

Cat. No. Product Name Purity Description Pricing
HY-P1650
Breceptin Breceptin (B 9870) is an antagonist of the bradykinin B1/B2 receptor (B1/B2R). Breceptin exhibits an irreversible antagonist effect on B2R, inhibiting the vasodilation induced by Bradykinin (HY-P0206) in the rabbit carotid vein contraction experiment. B-9870 shows partial agonist properties in HEK 293 cells with high expression of B2R, and can activate ERK1/2 phosphorylation, calcium ion mobilization, arachidonic acid release, and receptor internalization. Breceptin can be used in research to inhibit breast cancer and non-small cell lung cancer.
Pricing 
Expand Hide
loading...
/
  • /
loading...
Size Price
Stock Quantity Availability Operate
/
In-stock
(Estimated to ship on )
(Estimated to ship TODAY)
Estimated to ship on
(Estimated to ship TODAY)

Amount:

USD 0.00

This product is a controlled substance and not for sale in your territory.

This product is not for sale in your territory.

This compound is listed in the SVHC (Substances of Very High Concern) candidate list of ECHA (European Chemicals Agency).

Pricing 
Expand Hide

References